Pivotal study showing talimogene laherparepvec showed durable response rates in metastatic melanoma published
Amgen has announced the publication of primary results from the Phase 3 OPTiM study in the Journal of Clinical Oncology (JCO).
Category Archives: Melanoma / Skin Cancer
Similarities between cancerous and normal skin cells
Normal human skin cells harbor a surprisingly large number of un-inherited mutations that crop up over time, including many known cancer-promoters that help to drive tumor growth, researchers say.
Study examines occupational sun-safety policies for local government workers in Colorado
Few local government organizations in Colorado had policies on environmental controls, such as the provision of outdoor shade, or administrative procedures, including training and resource...
Sun safety: how to protect your child from the greatest cause of skin cancer
One of the best ways to protect your child from skin cancer is to protect them against UV radiation. We provide some tips on how this can be done.
First extensive description of the human secreted miRNome
In an elaborate study, biologists of the University of Luxembourg have found out that small molecules named microRNAs are, against many hopes, not yet suitable for early diagnosis of skin cancer...
Scientists identify promising new melanoma treatment strategy
Scientists looking to better understand the mechanisms behind the origin and spread of melanoma tumors have uncovered a possible role for a decades-old antibacterial agent in treating these...
Trial of new ‘resistance-busting’ skin cancer drug begins as first patient receives treatment
A patient has become the first to receive a new 'resistance-busting' experimental skin cancer drug with the launch of a phase I clinical trial.
VivoSight OCT clinical study: Results demonstrate clinical value of OCT in basal cell carcinoma diagnosis
Michelson Diagnostics, the UK-based medical device company focused on multi-beam Optical Coherence Tomography ('OCT') technology, announces the publication on-line in the British Journal of...
EU study to help understand if Intratumoral CD8+ T lymphocytes can predict outcomes in patients with previously untreated stages IIIb to IV melanoma
Amgen has announced the initiation of a clinical trial, NCT02366195, to determine whether baseline CD8+ T lymphocytes density is a biomarker of response to talimogene laherparepvec, an...
Phase III study: Pembrolizumab demonstrates superior survival, progression free survival and overall response rate compared to Ipilimumab
MSD (known as Merck & Co Inc. in the United States and Canada) has announced results from the randomised, pivotal Phase 3 study, KEYNOTE-006 which compared pembrolizumab to ipilimumab in patients...